HIGHLIGHTS
- who: Ben Gombe and collaborators from the College, London, United Kingdom, IAVI, New York, New York, United States of America, London School have published the research work: Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial, in the Journal: PLOS ONE of 23/09/2022
- what: The authors report the validation of two ELISAs for CN54gp140 and AIDSVAX BE at Uganda Virus Research Institute that demonstrates precision specificity and robustness for assessing the reciprocal antibody end point . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.